Brokerages Set OnKure Therapeutics, Inc. (NASDAQ:OKUR) Price Target at $32.00

OnKure Therapeutics, Inc. (NASDAQ:OKUR) has been assigned a consensus rating of “Hold” from the five brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $32.00.

Several equities research analysts recently weighed in on OKUR shares. Wall Street Zen raised OnKure Therapeutics to a “sell” rating in a report on Saturday, November 1st. Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd.

OnKure Therapeutics Stock Down 2.0%

OKUR opened at $2.41 on Tuesday. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $6.18. The business has a 50 day moving average price of $2.89 and a two-hundred day moving average price of $2.79. The company has a market cap of $32.66 million, a PE ratio of -0.50 and a beta of 0.46.

Institutional Investors Weigh In On OnKure Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in OnKure Therapeutics during the 2nd quarter worth approximately $25,000. Bailard Inc. acquired a new stake in shares of OnKure Therapeutics in the 2nd quarter valued at approximately $34,000. Jane Street Group LLC purchased a new stake in shares of OnKure Therapeutics in the fourth quarter valued at approximately $56,000. Rangeley Capital LLC acquired a new position in OnKure Therapeutics during the second quarter worth $71,000. Finally, GSA Capital Partners LLP raised its position in OnKure Therapeutics by 172.1% in the third quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock worth $163,000 after acquiring an additional 37,459 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.